Coupling the therapeutic potential of psilocybin with compound patent protection.
Psilocybin is under clinical development by multiple companies for its neuropsychiatric effects.
D-Psilocybin is unique in several ways:
D-Psilocybin may reduce the action of MAO-A on psilocin, potentially resulting in improved pharmacokinetics.
D-Psilocybin would be eligible for separate NCE status and would not be constrained by third party exclusivity.